RSV Seasonal Vaccine Introduction and Growth Strategy
HT 2023
Momentum drives upgraded
guidance
Delivered 11% sales growth,
9%' adj. operating profit growth
Profitable, resilient growth across
portfolio:
Vaccines 12%¹
•
Specialty Medicines 12%¹
General Medicines 8%
62%² of H1 2023 sales Vaccines and
Specialty Medicines
New products launched since 20173
delivered £4.6 billion with c.70% from
Vaccines and HIV
GSK
Absolute values at actual exchange rates (AER); changes at CER, unless stated otherwise. 1.
Excluding COVID-19 solutions 2.. Products include: Zejula, Blenrep, Jemperli, Cabenuva,
Apretude, Benlysta, Bexsero, Menveo, Menjugate, Nucala, Trelegy, Dovato, Juluca, Shingrix 3.
Product approvals since 2017 include: Zejula, Trelegy, Shingrix, Juluca, Dovato, Duvroq, Rukobia,
Blenrep, Cabenuva, Jemperli, Apretude
Q2 2023 performance
Sales
£7.2bn, +4%
+11%¹
Adj. EPS
38.8p, +16%
+17%¹
Adj. operating profit
£2.2bn, +11%
+12%¹
Dividend per share
14.0p
Full-year 2023 guidance upgraded¹
Sales growth: 8-10%
Adj. operating profit growth: 11-13%
Adj. EPS growth: 14-17%
5
STView entire presentation